{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:46:45Z","timestamp":1786373205934,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"name":"Kidney Research Scientist Core Education and National Training Program","award":["2019KP-NIA626990"],"award-info":[{"award-number":["2019KP-NIA626990"]}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>The optimal ambulatory management of renin-angiotensin-aldosterone system inhibitor (RAASi)\u2013related hyperkalemia to reduce the risk of recurrence is unknown. We examined the risk of hyperkalemia recurrence on the basis of outpatient pharmacologic changes following an episode of RAASi-related hyperkalemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      We performed a population-based, retrospective cohort study of older adults (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =49,571; mean age 79 years) who developed hyperkalemia (potassium \u22655.3 mEq\/L) while on a RAASi and were grouped as follows: no intervention, RAASi discontinuation, RAASi dose decrease, new diuretic, diuretic dose increase, or sodium polystyrene sulfonate within 30 days. The primary outcome was hyperkalemia recurrence, with secondary outcomes of cardiovascular events and all-cause mortality within 1 year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among patients who received a pharmacologic intervention (23% of the cohort), RAASi discontinuation was the most commonly prescribed strategy (74%), followed by RAASi decrease (15%), diuretic increase (7%), new diuretic (3%), and sodium polystyrene sulfonate (1%). A total of 16,977 (34%) recurrent hyperkalemia events occurred within 1 year. Compared with no intervention (35%, referent), the cumulative incidence of recurrent hyperkalemia was lower with RAASi discontinuation (29%; hazard ratio, 0.82; 95% confidence interval, 0.78 to 0.85), whereas there was no difference with RAASi dose decrease (36%; hazard ratio, 0.94; 95% confidence interval, 0.86 to 1.02), new diuretic (32%; hazard ratio, 0.95; 95% confidence interval, 0.78 to 1.17), or diuretic increase (38%; hazard ratio, 0.99; 95% confidence interval, 0.87 to 1.12) and a higher incidence with sodium polystyrene sulfonate (55%; hazard ratio, 1.30; 95% confidence interval, 1.04 to 1.63). RAASi discontinuation was not associated with a higher risk of 1-year cardiovascular events (hazard ratio, 0.96; 95% confidence interval, 0.91 to 1.02) or all-cause mortality (hazard ratio, 1.05; 95% confidence interval, 0.96 to 1.15) compared with no intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among older adults with RAASi-related hyperkalemia, RAASi discontinuation is associated with the lowest risk of recurrent hyperkalemia, with no apparent increase in short-term risks for cardiovascular events or all-cause mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.12990820","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T15:10:25Z","timestamp":1613747425000},"page":"365-373","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":34,"title":["Ambulatory Treatments for RAAS Inhibitor\u2013Related Hyperkalemia and the 1-Year Risk of Recurrence"],"prefix":"10.2215","volume":"16","author":[{"given":"Gregory L.","family":"Hundemer","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Talarico","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5075-6370","authenticated-orcid":false,"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia J.","family":"Leon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-6195","authenticated-orcid":false,"given":"Sarah E.","family":"Bota","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg A.","family":"Knoll","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How dangerous is hyperkalemia?","volume":"28","author":"Montford","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0002-9149(75)90001-6","article-title":"Atrioventricular and intraventricular conduction in hyperkalemia","volume":"35","author":"Bashour","year":"1975","journal-title":"Am J Cardiol"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0002-9343(46)90052-6","article-title":"Clinical syndrome of potassium intoxication","volume":"1","author":"Finch","year":"1946","journal-title":"Am J Med"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.01150112","article-title":"Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic","volume":"7","author":"Sarafidis","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","article-title":"Hyperkalemia in heart failure","volume":"68","author":"Sarwar","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"Nilsson","year":"2017","journal-title":"Int J Cardiol"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.kint.2015.11.018","article-title":"Treatment of hyperkalemia: Something old, something new","volume":"89","author":"Sterns","year":"2016","journal-title":"Kidney Int"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"B16-20241015","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"e0218739","DOI":"10.1371\/journal.pone.0218739","article-title":"Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study","volume":"14","author":"Adelborg","year":"2019","journal-title":"PLoS One"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.jacc.2012.06.062","article-title":"Myocardial recovery and the failing heart: Myth, magic, or molecular target?","volume":"60","author":"Mann","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: Predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ckj\/sft158","article-title":"Severe hyperkalaemia: Demographics and outcome","volume":"7","author":"Phillips","year":"2014","journal-title":"Clin Kidney J"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2215\/CJN.06290616","article-title":"The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals","volume":"12","author":"Hughes-Austin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","article-title":"Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: A systematic review","volume":"126","author":"Harel","year":"2013","journal-title":"Am J Med"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","article-title":"Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age","volume":"179","author":"Noel","year":"2019","journal-title":"JAMA Intern Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.12990820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:34Z","timestamp":1786369414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.12990820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12990820","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"2020-08-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}